




Post-ATS Combined Pulmonary Fibrosis and Emphysema (CPFE): Bad and Ugly All The Same?

2019-06-15

長庚醫院 胸腔內科 林鴻銓 Lin, Horng-Chyuan Department of Thoracic Medicine Chang Gung Memorial Hospital Chang Gung University, Taiwan




Interstitial Lung Disease Among US Veterans: Pilot Study of a Prospective Registry



Am J Respir Crit Care Med 2019;199:A3370

CPFE 2005




Eur Respir J 2005; 26: 586–593


Emphysema

Centrilobular emphysema Paraseptal emphysema Bullae


A




Fibrotic changes Honeycombing Reticular opacities Traction bronchiectasis Ground-glass opacities Architectural or bronchial distortion



Eur Respir J 2005; 26: 586-593



CPFE Related to Systemic Sclerosis



Years

SSc-Other	202	184	170	147	116	64
SSc-emphysema	29	28	26	25	17	8
SSc-ILD	196	180	158	133	100	50
SSc-CPFE	43	39	35	29	18	9

RMD Open 2019;5:e000820

Complications

19.8% in CPFE+lung cancer27.3% during surgery20% during chemotherapy16.7% during radiation

Acute lung injury

47-90% in CPFE50% in COPD31-46% in advanced IPF


Pulmonary arterial hypertension (PAH)

The mortality rate and median survival time from onset of ALI: **75%** and **22 days**


35.8-46.8% in CPFE **6.8-10.8%** in COPD **22.4-31.3%** in IPF

Lung cancer

J Thorac Dis 2015;7(4):767-779




IPF and Lung Cancer



Lung cancer in IPF

- **1. Most commonly SQCC**
- 2. Presents in elderly heavy smokers with a male
- **3.** Locating in peripheral regions and the lower part of lung predominance




CPFE Syndrome and Lung Cancer


Operative Outcomes

Operati	ve Outco	omes		All Cases $(n = 685)$		ormal = 387)	Emphysema (n = 222)	Fibro (n = 1		CPFE (n = 57)	p Value
Surgical	l procedu	ure									0.294
Lobec	tomy		90).2 (618)	89.7	(347)	89.6 (199)	89.5 (17)) 9	96.5 (55)	
Operati	on time,	minute	es 234	4.1 (31–873	3) 214.1	(31–583)	265.0 (61-873)	241.4 (11	6–519) 25	50.6 (137–505)	0.001
Blood tr	ransfusio	n	3	3.2 (22)	1.8	(7)	5.4 (12)	10.5 (2)		1.8 (1)	0.031
Postope	rative ou	utcomes	3								
Prolo	nged oxy	gen th	erapy 27	7.0 (185)	17.1	(66)	40.1 (89)	26.3 (5)	4	43.9 (25)	0.001
Complie	cations ^a		21	1.0 (144)	14.7	(57)	26.6 (59)	31.6 (6)	3	38.6 (22)	0.001
Arrhy	/thmia		10).1 (69)	7.5	(29)	12.2 (27)	15.8 (3)		17.5 (10)	0.043
Minit	racheost	omy	2	2.9 (20)	1.8	(7)	4.5 (10)	5.3 (1)		3.5 (2)	0.132
D. 1		11.b			0.1	(0)	4.1.(0)	10 E (3)			0.000
	A	cute	Lung Inju	ıry				Onset of ALI		Death	Death Due
Case			- 1		TSCT	Fibrosis	Emphysema	Within		Due	to Lung
No.	Age	Sex	Procedure	pStage	Findings	Grade	Grade	30 Days	Outcomes	to ALI	Cancer
1	76	Male	Lobectomy	Ι	CPFE	1	1	Yes	Dead	Yes	No
2	81	Male	Lobectomy	II	CPFE	2	1	Yes	Dead	Yes	No
3	83	Male	Lobectomy	III	CPFE	1	1	Yes	Alive	NA	NA
4	77	Male	Lobectomy	III	CPFE	2	1	No	Dead	No	Yes
5	72	Male	Lobectomy	III	CPFE	1	1	No	Dead	Yes	No
6	76	Male	Lobectomy	II	CPFE	1	1	No	Alive	NA	NA

Ann Thorac Surg 2016;102:440–7

CPFE Syndrome and Lung Cancer





Nature Reviews Disease Primers volume 3: 17074 (2017); Lancet 2017; 389: 1941–52

CPFE

Radiographic characteristic

Respiratory Medicine 117 (2016) 14-16

Emphysema in the upper zones and fibrosis in the bases

Progressive transition between emphysema and fibrosis

Paraseptal emphysematous lesions at the bases of the lungs within the fibrotic lesions


Large thick-walled cystic lesions (diameter \geq 1 cm) delineated by a 1-mm-thick wall. These cysts can be situated either in the upper lungs just beneath the chest wall or grow within the areas of reticulation and/or honeycombing


Centrilobular nodules which correspond to airway-centered fibrosis, (i.e. fibrotic changes along the respiratory bronchioles)

Subpleural curvilinear opacities

Ground Glass opacities

Findings suggestive of pulmonary hypertension (i.e. dilatation of the central pulmonary arteries, enlargement of the right heart, reduction of peripheral branches of the pulmonary arteries and mosaic appearance of the pulmonary parenchyma)





CPFE

Radiographic characteristic

Emphysema in the upper zones and fibrosis in the bases

Progressive transition between emphysema and fibrosis

Paraseptal emphysematous lesions at the bases of the lungs within the fibrotic lesions

Large thick-walled cystic lesions (diameter \geq 1 cm) delineated by a 1-mm-thick wall. These cysts can be situated either in the upper lungs just beneath the

chest wall or grow within the areas of reticulation and/or honeycombing

Centrilobular nodules which correspond to airway-centered fibrosis, (i.e. fibrotic changes along the respiratory bronchioles)

Subpleural curvilinear opacities

Ground Glass opacities

Findings suggestive of pulmonary hypertension (i.e. dilatation of the central pulmonary arteries, enlargement of the right heart, reduction of peripheral branches of the pulmonary arteries and mosaic appearance of the pulmonary parenchyma)

SRIF

CPFE

Pathological findings

Diffuse form of smoking-related interstitial lung disease: Overlap of pulmonary emphysema and fibrotic interstitial pneumonia (UIP or f-NSIP) Localized form of smoking-related interstitial lung disease: Presence of emphysema with fibrosis, air space enlargement with fibrosis, or occult fibrosis of smokers


Fibrotic lesions along bronchioles around the emphysematous areas

Thick-walled cystic lesions involving one or more acini characterized by dense wall fibrosis, and occasional fibroblastic foci, surrounded by honeycombing and normal alveoli

Occult fibrosis of smokers or smoking related interstitial fibrosis (SRIF): Alveolar septal widening by collagen deposition along with emphysema and respiratory bronchiolitis both in subpleural areas and in deeper parenchyma, surrounded or not by emphysematous lesions


Respiratory Medicine 117 (2016) 14-16

The European IPF Registry (eurIPFreg)



Respiratory Research (2018) 19:141

Australian IPF Registry - Antifibrotic Therapy May Improve Survival, Regardless of Disease Severity




Australian IPF Registry:

- The mortality rate across all patients after 4 years was 44%
- GAP stage was a strong predictor of mortality

Patients receiving antifibrotics had better survival (HR 0.56, 95% Cl 0.34–0.92, P=0.02), irrespective of underlying disease severity

CI, confidence interval; HR, hazard ratio

Jo HE et al. Eur Respir J 2017;49:1601592



FVC less relia Eur Respir J 2011; Pulmonar Fibrosis	38: 176–1		Pulmonary Emphysema	Respiratory Medicine 117 (2016) 14-26
	IPF	CPFE		Emphysema
Pulmonary function tests		Higher lu	ing volumes by 5–10%	6
FEV ₁	Ļ	↓ or N A	n J Respir Crit Care Med 1997; 155:136	7–1375.
FVC	Ļ	↓ or N		Ļ
FEV _{1/} FVC	1	\downarrow or \uparrow or	r N	Ļ
TLC	\downarrow	\downarrow or \uparrow or	r N	↑
FRC	\downarrow	\downarrow or \uparrow or	r N	↑
RV	Ļ	↓ or ↑ o	r N	1
DLCO	\downarrow	↓↓ Low	er DLCO by ~15%	Ļ
Desaturation during exercise	+		spir Crit Care Med 1997; 155:1367–137	_{75.} +
CT findings				
Emphysema	—	+		+
Fibrosis	+	+		_
Pathological findings	UIP	UIP or f-	NSIP + Emphysema	Emphysema
Pulmonary Hypertension	+	++ > 50	% Eur Respir J 2010; 35: 105–111.	+
Lung cancer risk	++	++		+


Prognosis of IPF FVC Decline and Mortality

Decline in %FVC in the preceding 24 weeks	Mortality in the subsequent 48 weeks
0-4.9 %	5 %
5 – 9.9 %	12 %
> 10 %	24 %
	du Bois et al, AJRCCM 2011
Less Reliat	ole in CPFE

Eur Respir J 2011; 38: 176–183

			monary rosis	C	PFE Pulmonar Emphyse	-			
Group	$\frac{\text{CPFE}}{(N=87)}$	IPF (<i>N</i> = 105)	Chi-square value	Р	Group	CPFE (<i>N</i> = 87	IPF (<i>N</i> = 105)	Chi-square value	Р
Age, years	66 ± 8.5	60 ± 4.3	0.63	<0.0001*	Finger clubbing	13	11	0.87	0.3516
Male	76	66	14.83	0.0001	Wheeze	55	12	56.17	<0.0001
BMI < 18 kg/m ²	37	39	0.58	0.4475	Basal crackles	47	97	37.34	< 0.0001
Smokers	75	44	39.63	< 0.0001	_	<u> </u>	6		
History of viral infection	13	37	10.18	0.0014	CEA increasing	21	-	49.11	<0.0001
Diabetes	16	10	3.19	0.0739	5-year survival, %	43.42 (33/76)	65.56 (59/90)	9.37	0.023
Cardiovascular and cerebrovascular diseases	67	63	6.29	0.0121				14.22	-0.001
Cancer	8	8	0.15	0.694	All-cause mortality, %	56.58 (43/76)	34.44 (31/90)	14.33	<0.001
Cor pulmonale	21	25	0.01	0.9577	Direct-cause mortality, %	39.47	23.33	22.14	< 0.001
РАН	39	45	0.08	0.7841		(30/76)	(21/90)		

BMC Pulmonary Medicine (2016) 16:137



BMC Pulmonary Medicine (2016) 16:137

BMJ Open Resp Res 2016;3: e000099


	CPFE (n=17)	COPD (n=49)	p Value
Age, years	76.5±7.1	73.4±9.0	0.209
Males, n (%)	15 (88.2)	36 (73.5)	0.318
Smoking index	989.7±574.1	1304.2±745.4	0.119
Former smokers, n (%)	16 (94.1)	41 (83.7)	0.428
Current smokers, n (%)	1 (5.9)	8 (16.3)	
Body mass index, kg/m ²	21.0±2.9	20.0±4.0	0.324
MRC grade (1/2/3/4/5)	0/0/8/8/1	0/2/25/18/4	0.613
Home oxygen therapy, n (%)	10 (58.8)	26 (53.1)	0.898
Emphysema score	9.1±3.2	13.1±5.0	< 0.005
Pulmonary function			
FVC, litres	2.1±0.5	1.8±0.7	0.136
FVC, %predicted	67.2±15.9	59.3±18.7	0.124
FEV ₁ , litres	1.7±0.4	0.8±0.5	< 0.0001
FEV ₁ , %predicted	70.6±14.2	33.8±16.6	< 0.0001
FEV ₁ /FVC, %	82.8±10.1	44.4±13.9	< 0.0001
PASP, mm Hg	54.2±26.1	42.7±10.2 (n=45)	0.016
6 min walk test	n=15	n=44	
Distance, m	270.5±59.4	216.0±99.1	0.054
SpO ₂ nadir, %	85.1±8.6	87.8±6.5	0.221
Borg scale	3.9±1.5	5.2±2.1	0.035
Short Form-36	n=16	n=45	
Physical function	38.3±23.7	31.9±19.6	0.299
Role-physical	36.8±27.9	31.1±25.2	0.451
Body pain	60.1±29.0	51.4±26.9	0.280
General health	40.4±18.1	32.6±18.3	0.143
Vitality	42.2±24.8	29.3±19.8	0.041
Social functioning	57.8±33.8	56.1±30.3	0.852
Role-emotional	37.0±27.0	31.7±28.7	0.521
Mental health	56.3±19.4	43.6±22.8	0.053

Patterns of Exacerbations


iysema (COPD)	CPFE			IPF
AE-COPD		A	E-IPF	
	CPFE	(n=83)	IPF (n=112)	P value
	AE-COPD	AE-IPF	AE-IPF	
Acute Exacerbation pre transplant	22/83 (2	26.15%)	45 (40.18%)	0.047
	10/83 (12%)	12/83 (14.4%)		*<0.05
Rate of exacerbation per year	0.33 (+	+/- 0.9)	0.43 (+/- 1.2)	0.5
Need for mechanical ventilation	10/22	(45%)	20/45 (44.44%)	0.938
	2/22 (9%)	8/22 (36%)		* 0.004
\$Need for mechanical ventilation and ECMO	3/22 (1	13.6%)	17/45 (37.8%)	0.043
	0/22 (0%)	3/22 (13.6%)		*<0.05

* P value comparing AE-COPD in the CPFE group vs AE-IPF in the IPF group. Am J Respir Crit Care Med 2019;199:A3368


CPFE Phenotypes




Respiratory Medicine 117 (2016) 14-26




TGF-ß Signaling in Lung Health and Disease




Int. J. Mol. Sci. 2018, 19, 2460




Int. J. Mol. Sci. 2018, 19, 2460



Caveolin-1 in Fibrosis



Front. Pharmacol., 24 August 2017




fibroblasts and emphysema formation alternating Propagation of EMT and collagen deposition

Am J Respir Crit Care Med 2019;199:A523


Early Diagnosis of IPF

Functional Respiratory Imaging (FRI)




Respir Res. 2018 Nov 6;19(1):213.

Quantitative CT Analysis




PLoS One. 2019 Mar 21;14(3):e0214278.




Eur Respir J 2017; 50: 1700379

Cardiopulmonary Exercise Testing (CPET) in CPFE




Am J Respir Crit Care Med 2019;199:A7139

Physiological Response to Exercise and Vital Prognosis in CPFE



Similar regarding peak values of oxygen uptake, workrate, heart rate, oxygen pulse, ventilation, ventilatory threshold, dyspnea and ventilation/CO₂ production slope


Am J Respir Crit Care Med 2019;199:A7140




Lung transplantation

Eur Respir J 2010;35:105-11 Arthritis Rheum 2011;63:295-304 J Thorac Dis 2015;7(4):767-779

Treatment of IPF



Treatment of Emphysema



J Thorac Dis 2015;7(4):767-779


Effect of Pulmonary Rehabilitation on CPFE and COPD

CPFE COPD Pre-PR Post-PR p Value Post-PR p Value Pre-PR CPFE COPD COPD CPFE 500 450 450 20 400 PF 400 350 15 VT RE 350 PF MH 10 300 RP GH SF 300 250 5 250 200 0 200 RP 150 -5 150 GH MH BP RE RP VT 100 -10 100 50 50 -15 0 0 -20 Before PR SF After PR Before PR After PR -25 \triangle 6MWD: 30.2 ± 55.6 $\triangle 6$ MWD: -16.6 ± 58.4 Mental health 56.3 ± 19.4 53.1 + 23.9Mental health 42.7 + 24.1 50.8 ± 21.9 0.034 0.539 FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity;


PR, pulmonary rehabilitation.

PR, pulmonary rehabilitation.

BMJ Open Resp Res 2016;3: e000099




Am J Respir Crit Care Med 2019;199:A1965




Am J Respir Crit Care Med 2019;199:A5071

Investigational Therapies for Severe IPF (CPFE?)




Reassessment during disease course



The Worst of Both Worlds (Bad and Ugly)

Combined Pulmonary Fibrosis and Emphysema Syndrome



Ann Transl Med 2016;4(10):196